News Focus
News Focus
icon url

DewDiligence

11/17/16 11:09 AM

#206160 RE: DewDiligence #205771

MNTA’s CEO says M230 is the most exciting compound in the company’s pipeline; this PR explains what it is:

http://finance.yahoo.com/news/momenta-pharmaceuticals-announces-publication-design-130000320.html
icon url

DewDiligence

11/26/16 12:29 PM

#206367 RE: DewDiligence #205771

MNTA—Index re potential competition for generic Copaxone:

#msg-126811385